ReviewFrontiers in pharmacology2013
The potential of polymeric micelles in the context of glioblastoma therapy.
Review in Frontiers in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review.International journal of nanomedicine · 2020Pooled it
- Redox-Sensitive Camptothecin Prodrug: A Promising Drug Delivery Strategy with Ultrahigh Drug Loading and Tunable Drug Release.Nano TransMed · 2025Article
- Polymeric nanocarriers for therapeutic gene delivery.Asian journal of pharmaceutical sciences · 2025Review
- Polymeric Micelles in Colorectal Cancer Therapy: A Comprehensive Review of Nano-drug Delivery Strategies, Copolymer Types, Physicochemical Characteristics, and Therapeutic Applications.Current medicinal chemistry · 2025Review
- Zinc-Modified Titanate Nanotubes as Radiosensitizers for Glioblastoma: Enhancing Radiotherapy Efficacy and Monte Carlo Simulations.ACS omega · 2024Article
- Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.Cancer management and research · 2024Article
- Improving the Treatment Effect of Carotenoids on Alzheimer's Disease through Various Nano-Delivery Systems.International journal of molecular sciences · 2023Review
- Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Micelles as potential drug delivery systems for colorectal cancer treatment.World journal of gastroenterology · 2022Review
- Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.Pharmaceutics · 2022Review
- A Distinct Advantage to Intraarterial Delivery ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment.Frontiers in bioengineering and biotechnology · 2019Review
- Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Reducible Micelleplexes are Stable Systems for Anti-miRNA Delivery in Cerebrospinal Fluid.Molecular pharmaceutics · 2016Article
- Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.Nanomedicine (London, England) · 2016Article
- Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier.International journal of nanomedicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM), a type of malignant glioma, is the most common form of brain cancer found in adults. The current standard of care for GBM involves adjuvant temozolomide-based chemotherapy in conjunction with radiotherapy, yet patients still suffer from poor outcomes with a median survival of 14.6 months. Many novel therapeutic agents that are toxic to GBM cells in vitro cannot sufficiently accumulate at the site of an intracranial tumor after systemic administration. Thus, new delivery strategies must be developed to allow for adequate intratumoral accumulation of such therapeutic agents. Polymeric micelles offer the potential to improve delivery to brain tumors as they have demonstrated the capacity to be effective carriers of chemotherapy drugs, genes, and proteins in various preclinical GBM studies. In addition to this, targeting moieties and trigger-dependent release mechanisms incorporated into the design of these particles can promote more specific delivery of a therapeutic agent to a tumor site. However, despite these advantages, there are currently no micelle formulations targeting brain cancer in clinical trials. Here, we highlight key aspects of the design of polymeric micelles as therapeutic delivery systems with a review of their clinical applications in several non-brain tumor cancer types. We also discuss their potential to serve as nanocarriers targeting GBM, the major barriers preventing their clinical implementation in this disease context, as well as current approaches to overcome these limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.